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Interactive effect between endothelin-1 and nitric oxide
bioavailability
Danny Ramzy, MD, Laura C. Tumiati, BSc, Elissa Tepperman, BSc, Rohit Sheshgiri, BSc, Jessica Jackman, BSc,
Mitesh Badiwala, MD, and Vivek Rao, MD, PhDObjective: Cyclosporine A and corticosteroids are associated with many side effects,
such as endothelial dysfunction and transplant vasculopathy. We examined the effects
of cyclosporine A and hydrocortisone exposure on endothelial function of the rat
thoracic aorta.
Methods: Lewis rats were injected with cyclosporine A, hydrocortisone, cyclosporine
A 1 hydrocortisone, or intraperitoneal saline daily for 2 weeks. Endothelial-
dependent and independent vascular relaxation were assessed in isolated segments
of thoracic aorta, as well as endothelin-1–induced vasoreactivity. Protein expression
of endothelial nitric oxide synthase, endothelinA, and endothelinB receptors were also
determined in the thoracic aorta.
Results: Exposure to cyclosporine A and cyclosporine A1 hydrocortisone resulted in
a reduction in endothelial-dependent vasorelaxation compared with control and
hydrocortisone (P 5 .001). Cyclosporine A and hydrocortisone-treated rats
demonstrated increased vasoreactivity to endothelin-1 compared with control,
whereas cyclosporine A1 hydrocortisone treatment resulted in a synergistic increase
(P5 .04). All treatment groups displayed a significant reduction in endothelial nitric
oxide synthase expression compared with control (P 5 .001). EndothelinA receptor
expression was increased in all treatment groups with a synergistic effect seen after
cyclosporine A1 hydrocortisone treatment. No differences were seen in endothelinB
receptor expression.
Conclusion: Cyclosporine A and hydrocortisone induce vasomotor dysfunction with
a synergistic impairment observed after concomitant exposure. Our findings suggest
that the resultant vasomotor dysfunction is the result of alterations in both nitric oxide
and endothelin-1 regulation.
C
yclosporine A (CyA) was the first antirejection drug that affected the results of
clinical heart transplantation by reducing the incidence and severity of rejec-
tion and remains an important component of modern immunosuppressive
therapy. Unfortunately, CyA is associated with many negative side effects, such as
nephrotoxicity, hepatotoxicity, neurotoxicity, and hypertension.1-3 Other adverse
effects include endothelial dysfunction and the development of transplant vasculop-
athy.1,4-10 CyA can influence transplant vasculopathy by increased plasma lipid
concentrations, causing hypertension, or by direct injury to the endothelium.10-13 It
is believed that the endothelial injury induced by CyA results in impaired vascular
homeostasis and transplant coronary disease.
The mechanisms by which CyA results in endothelial dysfunction are not fully
elucidated. However, CyA is known to impair vasodilation14-17 and may induce
vasoconstriction.18-20 Potential mechanisms resulting in vasospasm include the
increased release of vasoconstrictors or increased sensitivity to these vasoconstrictors.
One such vasoconstrictor is endothelin (ET)-1. The effect of CyA on plasma levels of
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TXAbbreviations and Acronyms
CyA 5 cyclosporine A
eNOS 5 endothelial nitric oxide synthase
ET 5 endothelin
Hcort 5 hydrocortisone
LV 5 left ventricular
NO 5 nitric oxide
Rc 5 receptor
SNP 5 sodium nitroprusside
TAo 5 thoracic aorta
ET-1 remains controversial. Most investigators have found
an increase in ET-1 levels after CyA treatment, although
this is not a consistent finding.15,19,21-27 Furthermore, altered
nitric oxide (NO) homeostasis may result in an impaired
vasodilatory response.15 Impaired NO homeostasis may be
a result of decreases in mRNA or protein expression of endo-
thelial nitric oxide synthase (eNOS) in CyA-treated patients.
Several investigators have demonstrated that eNOS RNA
expression is increased after CyA treatment,28 suggesting
that impaired NO production may be due to decreases in
eNOS protein synthesis or a shift to free radical production.29
There is also evidence that CyA generates free radicals.4
These free radicals may result in direct endothelial injury
and impaired vasomotor function.
Corticosteroids are another commonly used antirejection
agent also associated with several side effects. Corticoste-
roids can inhibit the release of vasodilators, such as histamine
and prostacyclin. We hypothesized that the combination of
CyA and corticosteroids (commonly used after solid organ
transplantation) results in a synergistic impairment of vascu-
lar function. Our investigations assessed the role of CyA, and
hydrocortisone (Hcort) on the development of endothelial
dysfunction in a rodent model of vascular injury. Although
these investigations have direct relevance to transplant
vasculopathy, we intentionally avoided a transplant model
to eliminate the confounding effects of immune-mediated
injury. Thus, these studies evaluate the drug-specific changes
to vascular function after sustained exposure. Specifically,
we examined the effects of CyA and Hcort exposure on
NO homeostasis and ET-1 signaling.
Materials and Methods
Animal care conformed to the ‘‘Canadian Council on Animal Care
Guide to the Care and Use of Experimental Animals’’ (National
Institutes of Health publication no 86-23, revised 1996).
Male Lewis rats (n 5 16) (200–300 g) were administered the
drug of interest (saline control, CyA (5 mg/kg) or Hcort (20 mg/
kg)) via peritoneal injection daily for a period of 2 weeks before
assessment of endothelial function. On the day of sacrifice, rats
were anesthetized using isoflurane. Median sternotomy was then
performed, the heart was excised for myocardial tissue sampling,
and segments of aorta were procured for assessment of endothelialThe Journal of Thfunction. Before heart excision, 1 mL of blood from the right ventri-
cle was collected for analysis of ET-1 plasma levels. The rats were
then exsanguinated under general anesthesia.
Endothelial Function Assessment
Endothelial-dependent and independent vascular relaxation were
assessed in isolated segments of thoracic aorta (TAo) after treat-
ment. The TAo was dissected, and vascular segments (5 mm in
length) were used for the assessment of in vitro vascular function
using a small vessel myograft for isometric tension recording. After
mounting the vessel on a pressure transducer, maximum vasocon-
striction was achieved with exposure to phenylephrine. After stabi-
lization, endothelial-dependent relaxation was assessed by
incremental exposure to acetylcholine. Endothelial-independent re-
laxation was assessed by incremental exposure to sodium nitroprus-
side (SNP). The maximum relaxation from phenylephrine-induced
vasoconstriction (Emax%) was compared between groups. ED50,
calculated as the concentration required to achieve half-maximum
vasorelaxation, was compared between groups. Sensitivity to vaso-
spasm was assessed in vessels following stabilization after SNP
washout. Incremental exposure to ET-1 was performed, and
%Cmax was calculated as the maximum increase in tension from
baseline. Each animal yielded 2 aortic segments. Data were included
if the variability between segments was less than 10%, and data were
averaged to yield 1 result per animal.
Plasma Measurements
Venous blood was aspirated from the right ventricle before exsan-
guination. CyA trough levels were performed on whole blood. For
ET-1 levels, blood samples were centrifuged (14,000 rpm) to collect
the plasma fraction, which was snap-frozen in liquid nitrogen and
stored at 280C. ET-1 in plasma was extracted using C18 Sep-
Pack (Waters Corporation, Milford, Mass) columns after acidifica-
tion with 1% trifluoroacetic acid. Plasma ET-1 levels were measured
using a commercial enzyme-linked immunosorbent assay (Biomed-
ica, Vienna, Austria).
Assessment of Oxidative Injury
8-isoprostane levels were measured as an indicator of free radical-
mediated injury.30 8-isoprostane is the stable end product of arach-
idonic acid oxidation generated by reactive oxygen species injury.31
Determination of 8-isoprostane levels in left ventricular (LV) myo-
cardial tissue was performed using a commercially available kit
(Cayman Chemical Company, Ann Arbor, Mich). The percentage
from baseline (LV from animals that received no intraperitoneal in-
jections) was calculated to compare differences between groups.
Western Blot Analysis
LV biopsies and the TAo were immediately collected after harvest-
ing. Biopsy specimens were snap-frozen in liquid nitrogen and
stored at 280C until analyzed. Biopsies were homogenized at
4C and prepared for analysis. Protein determination was deter-
mined by the method described by Bradford.32
Western blot determined the protein expression of inducible
NOS, eNOS, tumor necrosis factor-a, and transforming growth fac-
tor-b with the use of protein-specific monoclonal antibodies (BD
Biosciences, Mississauga, Canada) and ETA and ETB receptors
(Rc’s) with the use of protein-specific polyclonal antibodiesoracic and Cardiovascular Surgery c Volume 135, Number 4 939
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stacking and 10% running tris-glycine sodium dodecylsulfate–poly-
acrylamide gel electrophoresis gels. Gels were then transferred to
polyvinylidene difluoride membranes. Blocking was performed
for 1 hour at room temperature using blocking buffer. The blots
were exposed to the primary antibody for 12 hours at 4C and
then incubated with secondary antibody for 1 hour after washing.
Comparisons between groups were performed using densitometric
analysis. TAo densitometric data were corrected for b-actin expres-
sion, and LV data were corrected for glyceraldehyde-3-phosphate
dehydrogenase expression. No differences in b-actin and glyceral-
dehyde-3-phosphate dehydrogenase protein expression were seen
between groups at any time point.
Statistical Analysis
Statistical analysis was performed with the SAS statistical software
program V8.2 (SAS institute, Inc, Cary, NC). Continuous data were
analyzed by analysis of variance and are expressed as the mean
6 standard deviation. When the F-statistic of the analysis of vari-
ance was significant (P , .05), a Duncan’s multiple range test
was performed to specify differences between groups.
Results
All animals survived until the day of sacrifice with no
complications except for 1 rat with a gingival abscess in
the Hcort group. There was minimal variability from aortic
segments within each animal, and no animals were excluded
from the study. CyA levels in both treatment groups were
similar: CyA (61.7 6 11 ng/mL) and CyA 1 Hcort
(63.2 6 9 ng/mL).
Endothelial Function
Endothelial-dependent vasorelaxation of thoracic aortic rings
was impaired after CyA treatment compared with control
(Figure 1, A). CyA and CyA 1 Hcort treatment resulted in
an Emax% of 33% 6 2% and 30% 6 7%, respectively,
which was significantly (P5 .001) lower than that of control
at 46% 6 1%. However, isolated Hcort treatment (Emax%:
51% 6 1%) did not result in any significant impairment of
endothelial-dependent vasorelaxation compared with
control. Assessment of endothelial-independent Emax% to
SNP revealed no significant differences between groups
(P 5 .2) (Figure 1, B). However, when examining the
concentration of SNP necessary to achieve 50% of maximal
vasodilatory response, significant differences were seen
between groups. CyA-treated (ED50 3.2 3 10
28 6 0.2
mole/L) and CyA 1 Hcort-treated (ED50 4.0 3 10
28 6 0.3
mole/L) animals required approximately double the concen-
tration of SNP compared with both control (ED50 1.63 10
28
6 0.1 mole/L) and Hcort (ED50 1.3 3 10
28 6 0.1 mole/L)
(P5 .01). Differences between CyA1Hcort and CyA alone
were also significant (P , .05).
Significant differences were also found in vessel sensitiv-
ity to ET-1 exposure. Sensitivity to vasospasm (%Cmax) was
greater in CyA and Hcort-treated groups (P5 .04) compared
with control (CyA: 256% 6 11% vs Hcort: 238% 6 7% vs940 The Journal of Thoracic and Cardiovascular Surgery c ApFigure 1. A, Endothelial-dependent vasodilation in rat TAo. The
graph depicts the cumulative dose-response curves to acetylcho-
line in aortic segments. CyA and CyA1 Hcort treatment results in
impaired endothelial-dependent vasorelaxation compared with
Hcort and control. B, Endothelial-independent vasodilation in rat
TAo. The graph depicts the cumulative dose-response curves to
SNP in aortic segments. No differences in %Emax were seen be-
tween groups. C, Cumulative dose-response curves to ET-1 in aor-
tic segments of treated rats. Both CyA and Hcort increase
vasosensitivity to ET-1. Concomitant treatment synergistically in-
creases vessel sensitivity to ET-1. CyA, Cyclosporine A; Hcort, hy-
drocortisone; ET, endothelin; Con, control; Ach, acetylcholine.ril 2008
Ramzy et al Cardiothoracic Transplantationcontrol: 209% 6 7%) (Figure 1, C). Concomitant treatment
with CyA1Hcort (%Cmax: 348%6 10%) resulted in a syn-
ergistic increase in ET-1 induced vasospasm compared with
CyA and Hcort treatment alone.
Plasma Endothelin-1 Levels
Plasma ET-1 levels were not different between groups (CyA
1 Hcort: 1.0. 6 0.1 fmol/L vs CyA: 0.98 6 0.1 fmol/L vs
Hcort: 0.97 6 0.1f mol/L vs control: 0.97 6 0.1 fmol/L,
P5 .05). Control animals had an ET-1 plasma concentration
that is in the expected normal range.19
Oxidative Injury
CyA 1 Hcort and CyA treatment resulted in a greater
increase in oxidative injury as measured by changes in
8-isoprostane levels compared with both control and Hcort
groups (CyA 1 Hcort: 162% 6 9% vs CyA: 150% 6 6%
vs Hcort: 113% 6 2% vs control: 107% 6 4%, P 5 .05).
Endothelin Receptor Expression
Thoracic aortic ETA Rc protein expression was significantly
(P 5 .004) increased in all treatment groups compared with
control with concomitant treatment, resulting in an additive
increase in ETA Rc expression (Figure 2, A and B). However,
ETB Rc protein expression was not different between groups
(P 5 .29).
Nitric Oxide Synthase Expression
eNOS protein expression was lower in treated animals (CyA
and Hcort) compared with control (P , .001) (Figure 2, C).
However, CyA 1 Hcort exposure resulted in a significant
synergistic reduction in eNOS protein expression. However,The Journal of Thoinducible NOS expression was not induced in any of the
experimental groups.
Proinflammatory Cytokine Expression
Myocardial protein expression of tumor necrosis factor-a and
transforming growth factor-b did not differ between groups.
Discussion
CyA is the cornerstone of modern immunosuppressive ther-
apy despite its well-known side effects. Jeanmart and col-
leagues33 demonstrated that CyA results in impairment of
endothelial-dependent vasorelaxation in an in vitro model.
Sudhir and colleagues17 and Khalil and colleagues34 have
both shown in dogs that acute exposure to CyA impairs cor-
onary endothelial function. Their results also indicate that
NO dysregulation may be involved in CyA-induced dysfunc-
tion.17,34 Our study confirms that both CyA and Hcort result
in vasomotor dysfunction in an in vivo model. The mecha-
nisms of injury are different between the 2 agents, and
when they were administered concomitantly, we observed
a synergistic impairment of vascular function. The possible
mechanisms of vascular injury include direct oxidant injury,
increased cytokine release, and altered regulation of endothe-
lial NO production.
We demonstrated that CyA treatment significantly alters
normal vascular homeostasis as assessed by impaired endo-
thelial-dependent vascular dilatation. Normal vessel function
is maintained by the balance between NO and ET-1. Our
study revealed that CyA alters both NO and ET-1 regulation.
First, eNOS protein expression was reduced after treatment
with CyA, indicating a possible impairment in NO regulation.
The reduction in eNOS protein expression may beTXFigure 2. A, Quantitative Western blot
analysis of ETA Rc expression in the
TAo. All treatment groups showed in-
creased ETA Rc expression, with the
greatest increase observed in the CyA
1 Hcort group. B, Quantitative Western
blot analysis of ETB Rc protein expres-
sion in the TAo. No differences were ob-
served between groups. C, Quantitative
Western blot analysis of eNOS protein
expression in the TAo. Both CyA and
Hcort decreased eNOS expression,
with CyA 1 Hcort demonstrating a syn-
ergistic reduction. ET, Endothelin; Rc,
receptor; Con, control; CyA, cyclospor-
ine A; Hcort, hydrocortisone; eNOS, en-
dothelial nitric oxide synthase.racic and Cardiovascular Surgery c Volume 135, Number 4 941
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tidyl-prolyl isomerase function, resulting in impaired eNOS
folding and therefore increased degradation. Lungu and
colleagues35 showed that CyA also inhibits eNOS activity.
Second, although ET-1 levels were not elevated by CyA treat-
ment, ETA Rc protein expression in the TAo was significantly
increased with no concomitant change in ETB Rc protein ex-
pression. ETA Rc activation results in vasoconstriction,
whereas ETB Rc on endothelial cells results in vasodilation.
Therefore, an increased ETA Rc-to-ETB Rc ratio results in
greater vasoconstriction. Thus, CyA results in greater sensi-
tivity to ET-1–induced vasospasm. Hunley and colleagues36
showed in a rodent model that CyA-induced renal dysfunc-
tion was abrogated after treatment with BQ123, an ETA Rc
antagonist. Takeda and colleagues37 observed a similar find-
ing in mesangial cells where ET-1 antagonism protected
against CyA-induced injury. Therefore, ETA Rc up-regula-
tion may be a common pathway by which CyA results in in-
jury in various cell types. CyA also resulted in a higher SNP
ED50 compared with the other treatment groups, indicating
impaired cyclic guanosine monophosphate-dependent
smooth muscle cell relaxation. The study by Khalil and col-
leagues34 reinforces our observations. They demonstrated
that CyA impaired both endothelial-dependent and indepen-
dent vasodilation. Previous studies by Diederich and col-
leagues29 and Galle38 have suggested that CyA treatment
increases free radical production. In comparison with our in-
vestigations, the study by Diederich and colleagues29 used an
elevated dose of CyA (25 mg/kg), and the study by Galle and
colleagues38 was performed on isolated vascular rings and not
in an in vivo model. Our study confirmed that oxidative injury
(increased 8-isoprostane levels) occurred after even low-nor-
mal CyA exposure in an in vivo model. Oxidative injury may
also account for the smooth muscle dysfunction observed af-
ter CyA therapy. In addition, oxygen radicals can inhibit NO
production, worsening vascular homeostasis. Proinflamma-
tory cytokines can aggravate oxidative injury and represent
a possible mechanism of injury after either CyA or Hcort ex-
posure. However, we found no significant changes in myocar-
dial levels of either transforming growth factor-a or tumor942 The Journal of Thoracic and Cardiovascular Surgery c Apnecrosis factor-b, suggesting that a heightened inflammatory
response is not the cause of our observed derangements. Ad-
ditional markers of inflammation need to be assessed to con-
firm this conclusion.
Corticosteroids are also associated with impaired vasomo-
tor function. Unlike CyA, Hcort did not impair endothelial-
dependent vascular dilatation. However, Hcort did result
in a similar decrease in eNOS protein expression, indicat-
ing that impaired NO regulation seen with CyA may be
due to impaired enzyme function in addition to decreased
protein expression. There was no impairment in endothe-
lial-independent vasodilation with Hcort therapy. Hcort treat-
ment did result in increased sensitivity to ET-1. Hcort
exposure increased ETA Rc expression with no change in
ETB Rc expression. Unlike CyA, Hcort treatment did not re-
sult in oxidative injury. Thus, we speculate that CyA treat-
ment results in functional uncoupling of the eNOS enzyme
producing free radicals instead of NO. Furthermore, func-
tional uncoupling of eNOS by CyA may explain why similar
reductions in protein expression did not result in impaired en-
dothelial vasodilation with Hcort. Transplant recipients are
commonly given both a corticosteroid and CyA. We demon-
strated that Hcort therapy aggravates CyA-induced smooth
muscle dysfunction as indicated by worsened endothelial-
independent vasorelaxation and heightened sensitivity to
ET-1 vasospasm.
We have made the following novel observations (Table 1):
1. CyA results in alteration of both NO and ET-1 regula-
tion, leading to impairment of vasodilation and
increased sensitivity to vasospasm.
2. Hcort results in decreased eNOS expression and
increased ETA Rc expression, resulting in increased
sensitivity to vasospasm.
3. CyA results in direct oxidative injury to the endothe-
lium.
4. Corticosteroid treatment aggravates CyA-induced
vasomotor dysfunction.
Our findings suggest possible treatment strategies for im-
proving vasomotor function in patients receiving standard
immunosuppression. An effective strategy must includeTABLE 1. Summary of vascular effects of cyclosporine A, hydrocortisone, and cyclosporine 1 hydrocortisone
CyA Hcort CyA 1 Hcort
Vasoreactivity to ET-1 %Cmax 256% 6 11%* 256% 6 11%* 348% 6 10%*y
ET-1 levels 0.98 6 0.1 fmol/L 0.97 6 0.1 fmol/L 1.0. 6 0.1 fmol/L
ROS 150% 6 6%* 113% 6 2% 162% 6 9%*
ET-1 Rc A 133% 6 10%* 161% 6 5%* 181% 6 3%*y
ET-1 Rc B 108% 6 4% 96% 6 5% 103% 6 4%
Vasoreactivity to acetylcholine %Emax 33% 6 2%* 51% 6 1% 30% 6 7%*
eNOS 71% 6 3%* 67% 6 6%* 43% 6 5%*y
ROS 150% 6 6%* 113% 6 2% 162% 6 9%*
Rc, Receptor; ET, endothelin; ROS, reactive oxygen species; eNOS, endothelial nitric oxide synthase. *P, .05 versus control. yP, .05 versus CyA and Hcort.ril 2008
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This may be achieved by using an ET-1 antagonist (eg, bo-
sentan) and tetrahydrobiopterin, an essential eNOS cofactor,
for stabilizing the eNOS complex and reducing free radical
production. In the case of corticosteroids, an effective strat-
egy must include ET-1 antagonism and an NO donor. This
may be achieved by using bosentan and L-arginine, an NO
donor, to counterbalance the increased sensitivity to ET-1.
Our findings provide potential mechanisms for the develop-
ment of CyA and corticosteroid-induced hypertension, as
well as a direct mechanism by which CyA may lead to trans-
plant vasculopathy. Further studies will delineate the putative
beneficial effects of our proposed treatment strategies.
Conclusions
The present study was designed to investigate the direct effect
of our treatment groups on vascular function in the absence of
an immune response or a period of ischemia/reperfusion.
Clearly, the effects of the latter 2 variables will need further
assessment in a heterotopic transplant model. In addition,
we evaluated changes in aortic tissue as opposed to coronary
arteries. Although the responses are likely consistent, it is
possible that both CyA and Hcort exert differential effects
on coronary vasculature than seen in the TAo.
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Discussion
Dr Frank Sellke (Boston, Mass). I noticed for several of the param-
eters you looked at, in particular endothelial-dependent relaxation,
Hcort itself really didn’t have any effect, but when you added it to
CyA, it seemed to aggravate the detrimental effects. Why do you
see this added detrimental action of Hcort when by itself doesn’t
cause any impaired effect?
Dr Ramzy. When we looked at endothelial-dependent vasore-
laxation, we did not see a significant difference. There are 2 sides
to NO production: There is the expression of eNOS and the activity
of eNOS. Because of time constraints I did not show all our data.
CyA has direct inhibitory effects on eNOS in addition to its ability
to decrease its expression, whereas Hcort demonstrated decreased
expression with no change in activity. Thus, when we looked at en-
dothelial-dependent vasorelaxation, we did not find any significant
differences with Hcort. However, when we looked at Hcort’s effect
on sensitivity to ET-1, there was significantly aggravated ET-1–in-
duced vasospasm because it has the ability to up-regulate the ETA
receptor, which is made even worse when we add CyA. When we
combined the 2, the expression of eNOS is significantly decreased
compared with CyA alone. With the added effect of CyA directly
inhibiting eNOS activity, we end up with worsening endothelial
dysfunction.
DrChadwick Stouffer (Grand Rapids, Mich). In your 4 groups,
it looked like your ET-1 levels were all comparable. Can you com-
ment on your conclusion that that did affect homeostasis? How did
you look at the oxygen-free radical production in the CyA group?
Dr Ramzy. When we looked at the figure for ET-1 production,
the levels were the same in our 3 main groups. However, in a situa-
tion of decreased NO production (again, because of the time con-944 The Journal of Thoracic and Cardiovascular Surgery c Apstraint I did not demonstrate these data), our 3 main groups
impaired NO production. Under normal conditions with an inhibi-
tion of NO production, ET-1 levels should decrease. Therefore,
maintaining ET-1 levels at control levels is actually a relative in-
crease in ET-1; therefore, at those levels it was a relative elevation
of ET-1 compared with our control group. We measured ET-1 levels
at the same time we determined our trough levels for CyA, and sev-
eral studies have demonstrated that CyA on its own increases ET-1
levels in a concentration-dependent manner. As CyA levels change,
ET-1 production changes. Therefore, if we measure ET-1 levels at
peak concentration, I suspect we will see higher levels. Dr Takeda’s
group demonstrated that 6 weeks of CyA treatment elevated levels
of ET-1.
In addition to our data demonstrating free-radical injury, we also
looked at a cell culture model whether these drugs are able to pro-
duce free radicals, and CyA, as seen here, has the ability to increase
free-radical production compared with control.
Dr Mark Krasna (Towson, Md). Dr Ramzy, perhaps you could
just elaborate a little bit then on the possible modifications in treat-
ment strategies that you would use now?
Dr Ramzy. We actually performed additional studies looking at
whether our theories would actually work. Tetrahydrobiopterin
(BH4) is an essential cofactor for eNOS, and when we give this to
our CyA treatment group we do see a restoration to near normal
of vasomotor function in terms of endothelial-dependent vasorelax-
ation with BH4, demonstrating the importance of eNOS dimeriza-
tion. Therefore, CyA not only decreases eNOS expression but
also results in uncoupling of the enzyme, which produces more
free radicals than NO. The addition of Bosentan, an ET-1 antagonist,
completely restores endothelial-dependent vasorelaxation, and sim-
ilarly with endothelial-independent vasorelaxation, BH4 has the
ability to attenuate CyA effects. As you can see in this figure, there
is still a lag, indicating the NO side of the equation is not the only
player, that there is, in addition to NO impairment, another factor,
which our data suggest is ET-1. Thus, we believe that optimal ther-
apy should consist of both eNOS augmentation and ET-1 blockade.ril 2008
